Table Info

Table 5.

Enthalpy fit parameters of the supplied ADC samples

ADCs	ΔH Peak-1 (kJ/moL)	ΔH Peak-2 (kJ/moL)	ΔH Peak-3 (kJ/moL)	ΔH Peak-4 (kJ/moL)
Trastuzumab		660		3,800
T-DM1		334	618	2,454
Trastuzumab-MCC-maytansinoid (DAR = 4.1)		264	684	2,054
Trastuzumab-MC-VC-PAB-MMAE (DAR = 2.0)		370	890	2,300
Trastuzumab-MC-VC-PAB-MMAE (DAR = 4.0)	140	290	740	2,400

The standard deviation in the replicates was < 10% for all reported values, except trastuzumab-MC-VC-PAB-MMAE (DAR = 4.0), trastuzumab

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/100264_sup_1.pdf.

Declarations

Acknowledgments

The authors wish to thank our colleagues from Ajinomoto Bio-Pharma Services, Inc and Ajinomoto Co., Inc., as follows: Ms. Tawfiq Zhala for technical assistance for conjugation; Mr. Ryusuke Hirama for technical assistance with the AlogP analysis; Dr. Tatsuya Okuzumi for many helpful discussions and suggestions in ADC.

Author contributions

CQ, BAM, and YM contributed conception and design of the study and conducted AlopP analysis; TF conducted conjugation and HPLC studies; CR and CQ performed the DSC analysis; YM wrote the first draft of the manuscript; MK contributed analysis; and CQ, CR, and BAM reviewed and revised the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

Regarding this study, the authors and/or family members have no scientific or medical committee membership or relationship with their members, counseling, expertise, employment status in any company, shareholding, and similar situations.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Tarcsa E, Guffroy MR, Falahatpisheh H, Phipps C, Kalvass JC. Antibody-drug conjugates as targeted therapies: are we there yet? A critical review of the current clinical landscape. Drug Discov Today Technol. 2020. [DOI] [PubMed]

Matsuda Y, Mendelsohn BA. An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opin Biol Ther. 2021;21:963–75. [DOI] [PubMed]

Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2021;[Epub ahead of print]. [DOI] [PubMed]

Leung D, Wurst JM, Liu T, Martinez RM, Datta-Mannan A, Feng Y. Antibody conjugates-recent advances and future innovations. Antibodies (Basel). 2020;9:2. [DOI] [PubMed] [PMC]

Nicolaou KC, Rigol S. Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine. Nat Prod Rep. 2020;37:1404–35. [DOI] [PubMed] [PMC]

Newman DJ. Natural product based antibody drug conjugates: clinical status as of November 9, 2020. J Nat Prod. 2021;84:917–31. [DOI] [PubMed]

Chen H, Lin Z, Arnst KE, Miller DD, Li W. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22:1281. [DOI] [PubMed] [PMC]

Akaiwa M, Dugal-Tessier J, Mendelsohn BA. Antibody-drug conjugate payloads; study of auristatin derivatives. Chem Pharm Bull (Tokyo). 2020;68:201–11. [DOI] [PubMed]

Matsuda Y, Chakrabarti A, Takahashi K, Yamada K, Nakata K, Okuzumi T, et al. Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1177:122753. [DOI] [PubMed]

10.

Tawfiq Z, Caiazza NC, Kambourakis S, Matsuda Y, Griffin B, Lippmeier JC, et al. Synthesis and biological evaluation of antibody drug conjugates based on an antibody expression system: conamax. ACS Omega. 2020;5:7193–200. [DOI] [PubMed] [PMC]

11.

Matsuda Y, Mendelsohn BA. Recent advances in drug-antibody ratio determination of antibody-drug conjugates. Chem Pharm Bull (Tokyo). 2021;69:976–83. [DOI] [PubMed]

12.

Ghose A, Viswanadhan V, Wendoloski J. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods. J Phys Chem A. 1998;102:3762–72. [DOI]

13.

Matsuda Y, Tawfiq Z, Leung M, Mendelsohn BA. Insight into temperature dependency and design of experiments towards process development for cysteine-based antibody-drug conjugates. ChemistrySelect. 2020;5:8435–9. [DOI]

14.

Matsuda Y, Leung M, Tawfiq Z, Fujii T, Mendelsohn BA. In-situ reverse phased HPLC analysis of intact antibody-drug conjugates. Anal Sci. 2021;37:1171–6. [DOI] [PubMed]

15.

Tawfiq Z, Matsuda Y, Alfonso MJ, Clancy C, Robles V, Leung M, et al. Analytical comparison of antibody-drug conjugates based on good manufacturing practice strategies. Anal Sci. 2020;36:871–5. [DOI] [PubMed]

16.

Matsuda Y, Kliman M, Mendelsohn BA. Application of native ion exchange mass spectrometry to intact and subunit analysis of site-specific antibody-drug conjugates produced by AJICAP first generation technology. J Am Soc Mass Spectrom. 2020;[Epub ahead of print]. [DOI] [PubMed]

17.

Matsuda Y, Robles V, Malinao MC, Song J, Mendelsohn BA. Comparison of analytical methods for antibody-drug conjugates produced by chemical site-specific conjugation: first-generation AJICAP. Anal Chem. 2019;91:12724–32. [DOI] [PubMed]

18.

Matsuda Y, Clancy C, Tawfiq Z, Robles V, Mendelsohn BA. Good manufacturing practice strategy for antibody-drug conjugate synthesis using site-specific chemical conjugation: first-generation AJICAP. ACS Omega. 2019;4:20564–70. [DOI] [PubMed] [PMC]

19.

Matsuda Y, Leung M, Okuzumi T, Mendelsohn B. A purification strategy utilizing hydrophobic interaction chromatography to obtain homogeneous species from a site-specific antibody drug conjugate produced by AJICAP™ first generation. Antibodies (Basel). 2020;9:16. [DOI] [PubMed] [PMC]

20.

Matsuda Y. Current approaches for the purification of antibody-drug conjugates. J Sep Sci. 2021;[Epub ahead of print]. [DOI] [PubMed]

21.

Wakankar AA, Feeney MB, Rivera J, Chen Y, Kim M, Sharma VK, et al. Physicochemical stability of the antibody-drug conjugate trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem. 2010;21:1588–95. [DOI] [PubMed]

22.

Beckley NS, Lazzareschi KP, Chih HW, Sharma VK, Flores HL. Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjug Chem. 2013;24:1674–83. [DOI] [PubMed]

23.

Chen L, Wang L, Shion H, Yu C, Yu YQ, Zhu L, et al. In-depth structural characterization of kadcyla^® (ado-trastuzumab emtansine) and its biosimilar candidate. MAbs. 2016;8:1210–23. [DOI] [PubMed] [PMC]

24.

Sang H, Lu G, Liu Y, Hu Q, Xing W, Cui D, et al. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. Anal Chim Acta. 2017;955:67–78. [DOI] [PubMed]

25.

Matsuda Y, Malinao MC, Robles V, Song J, Yamada K, Mendelsohn BA. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1140:121981. [DOI] [PubMed]

26.

Yamazaki S, Shikida N, Takahashi K, Matsuda Y, Inoue K, Shimbo K, et al. Lipoate-acid ligase a modification of native antibody: synthesis and conjugation site analysis. Bioorg Med Chem Lett. 2021;51:128360. [DOI] [PubMed]

27.

Costoplus JA, Veale KH, Qiu Q, Ponte JF, Lanieri L, Setiady Y, et al. Peptide-cleavable self-immolative maytansinoid antibody-drug conjugates designed to provide improved bystander killing. ACS Med Chem Lett. 2019;10:1393–9. [DOI] [PubMed] [PMC]

28.

Wang Y, Liu L, Fan S, Xiao D, Xie F, Li W, et al. Antibody-drug conjugate using Ionized cys-linker-MMAE as the potent payload shows optimal therapeutic safety. Cancers (Basel). 2020;12:744. [DOI] [PubMed] [PMC]

29.

Yoder NC, Bai C, Tavares D, Widdison WC, Whiteman KR, Wilhelm A, et al. A case study comparing heterogeneous lysine- and site-specific cysteine-conjugated maytansinoid antibody-drug conjugates (ADCs) illustrates the benefits of lysine conjugation. Mol Pharm. 2019;16:3926–37. [DOI] [PubMed]

30.

Matsuda Y, Seki T, Yamada K, Ooba Y, Takahashi K, Fujii T, et al. Chemical site-specific conjugation platform to improve the pharmacokinetics and therapeutic index of antibody-drug conjugates. Mol Pharm. 2021;18:4058–66. [DOI] [PubMed]